(Q52551374)

3 May 2018

title

Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. (English)

1 reference

3 May 2018

7

Osheroff N

1 reference

3 May 2018

author name string

Burden DA

1

1 reference

3 May 2018

Kingma PS

2

1 reference

3 May 2018

Froelich-Ammon SJ

3

1 reference

3 May 2018

Bjornsti MA

4

1 reference

3 May 2018

Patchan MW

5

1 reference

3 May 2018

Thompson RB

6

1 reference

3 May 2018

language of work or name

English

0 references

publication date

1 November 1996

1 reference

3 May 2018

Journal of Biological Chemistry

published in

1 reference

3 May 2018

volume

271

1 reference

3 May 2018

issue

46

1 reference

3 May 2018

page(s)

29238-29244

1 reference

3 May 2018

Catalytic function of DNA topoisomerase II.

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Structure and function of type II DNA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Recent developments in DNA topoisomerase II structure and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA topoisomerases and models of sister-chromatid exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

The role of DNA topoisomerases in recombination and genome stability: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Segregation of recombined chromosomes in meiosis I requires DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Yeast DNA topoisomerase II is encoded by a single-copy, essential gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA topoisomerase II is required at the time of mitosis in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

The performance of short-term tests in identifying potential germ cell mutagens: a qualitative and quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Topoisomerase II enzymes and mutagenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Topoisomerase poisons: harnessing the dark side of enzyme mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Drug resistance associated with altered DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Topoisomerase II: A specific marker for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA topoisomerases: essential enzymes and lethal targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Etoposide: current status and future perspectives in the management of malignant neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA topoisomerase-trapping antitumour drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

DNA sequencing with chain-terminating inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

The binding of gyrase to DNA: analysis by retention by nitrocellulose filters

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Uncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.271.46.29238

21 January 2018

Identifiers

DOI

10.1074/JBC.271.46.29238

1 reference

3 May 2018

PubMed ID

8910583

1 reference

3 May 2018